Literature DB >> 3087282

Comparative study of serum bactericidal activity of cefotaxime alone or in combination with tobramycin.

M G Bergeron, M LeBel, A Charest, J F Forcier, J Morin, F Vallée.   

Abstract

The objectives of this study were to investigate the bactericidal activity in serum of cefotaxime alone or in combination with tobramycin against clinical strains and to determine the influence of tobramycin on the pharmacokinetics of cefotaxime. The peak bactericidal activity in serum of cefotaxime alone against Klebsiella oxytoca, Enterobacter aerogenes, Serratia marcescens, Pseudomonas cepacia, and Listeria monocytogenes varied between 1:4 and 1:256. Bactericidal activity could still be detected at 6 h against K. oxytoca and L. monocytogenes. The addition of tobramycin increased the bactericidal activity of cefotaxime against E. aerogenes from 1:16 to 1:128 (P less than 0.01). Cefotaxime recovery from urine was significantly decreased when tobramycin was added. Our data are comparable with those of other investigators who have shown a limited increase in the bactericidal activity of cefotaxime when aminoglycosides are added.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087282      PMCID: PMC176418          DOI: 10.1128/AAC.29.2.379

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Nonlinear least-squares regression programs for microcomputers.

Authors:  C C Peck; B B Barrett
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

Review 2.  Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy.

Authors:  J S Wolfson; M N Swartz
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

3.  The bactericidal activity in serum and its prognostic clinical value.

Authors:  J Klastersky
Journal:  Infection       Date:  1983       Impact factor: 3.553

4.  [Calculation of initial values of pharmacokinetic using a programmable calculator].

Authors:  P P Le Blanc; J Dumas
Journal:  Therapie       Date:  1983 Jan-Feb       Impact factor: 2.070

5.  Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.

Authors:  L B Reller
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

6.  Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime.

Authors:  R Quintiliani; C H Nightingale; R Tilton
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

7.  Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  H Lagast; S H Zinner; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

8.  Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration.

Authors:  C W Stratton; M P Weinstein; L B Reller
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

9.  Serum bactericidal activity of ceftazidime increased by netilmicin.

Authors:  M LeBel; M Pellerin; M G Bergeron
Journal:  Drug Intell Clin Pharm       Date:  1985-12
  9 in total
  2 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  Pacemaker lead endocarditis due to multidrug-resistant Corynebacterium striatum detected with sonication of the device.

Authors:  Alessandra Oliva; Valeria Belvisi; Marco Iannetta; Carolina Andreoni; Maria T Mascellino; Miriam Lichtner; Vincenzo Vullo; Claudio M Mastroianni
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.